On Sep 14, we issued an updated research report on
Cardiovascular Systems, Inc. ( CSII Quick Quote CSII - Free Report) . The company has been pursuing product improvements, as well as evaluating new technologies in a bid to strengthen and broaden its portfolio of powerful micro-invasive tools. However, cut-throat competition is a concern for the company. The stock currently carries a Zacks Rank #3 (Hold).
Over the past year, shares of Cardiovascular Systems have underperformed its
industry. The stock has gained 13.6% compared with the industry’s 33.2% rise.
Cardiovascular Systems’ sales performance was dismal in the fiscal fourth quarter. According to the company, amid the pandemic, there was a significant decline in STEMI activations as patients avoided hospitals and stayed home even when they were having a heart attack. Gross margin contraction and operating loss are concerning. A tough competitive landscape and the company’s failure to expand business overseas are the other headwinds.
On a positive note, worldwide peripheral revenues exceeded the company’s projections. Favorable outcomes of the REACH PVI study and launch of a physician finder are encouraging. Cardiovascular Systems has long been expanding its product portfolio to enhance its market reach and versatility.
Currently, the company is pursuing product improvements and evaluating new technologies to strengthen and broaden its portfolio of powerful micro invasive tools. In this regard, the Sapphire angioplasty balloons and Teleport Microcatheter are two offerings from the company, which have historically seen strong customer adoption. Also, Nitinol Coronary ViperWire, which was launched in Japan in 2019, remains an important revenue contributor to the company’s coronary segment.
Strong solvency and favorable market dynamics are added benefits. The company’s issuance of a revenue outlook for fiscal 2021 and expectations of steady recovery in coronary procedures are positives.
Stocks Worth a Look
Some better-ranked stocks from the broader medical space are QIAGEN N.V. (
QGEN Quick Quote QGEN - Free Report) , Thermo Fisher Scientific Inc. ( TMO Quick Quote TMO - Free Report) and Hologic, Inc. ( HOLX Quick Quote HOLX - Free Report) .
QIAGEN’s long-term earnings growth rate is estimated at 22.3%. It currently sports a Zacks Rank #1. (Strong Buy). You can see
the complete list of today’s Zacks #1 Rank stocks here.
Thermo Fisher’s long-term earnings growth rate is estimated at 15%. It currently carries a Zacks Rank #2 (Buy).
Hologic’s long-term earnings growth rate is estimated at 15.5%. The company presently sports a Zacks Rank #1.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time. See 8 breakthrough stocks now>>